APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-amyloid-β Monoclonal Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-amyloid-β Monoclonal Antibodies Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchAnti-amyloid-β Monoclonal Antibodies Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-amyloid-β Monoclonal Antibodies Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Anti-amyloid-β Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-amyloid-β Monoclonal Antibodies Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-amyloid-β Monoclonal Antibodies Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-amyloid-β Monoclonal Antibodies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-amyloid-β Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-amyloid-β Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-amyloid-β Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-amyloid-β Monoclonal Antibodies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-amyloid-β Monoclonal Antibodies market include Eisai, Eli Lilly and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-amyloid-β Monoclonal Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-amyloid-β Monoclonal Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-amyloid-β Monoclonal Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-amyloid-β Monoclonal Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-amyloid-β Monoclonal Antibodies Segment by Company

Eisai

Eli Lilly

Biogen

Anti-amyloid-β Monoclonal Antibodies Segment by Type

Lecanemab

Donanemab

Anti-amyloid-β Monoclonal Antibodies Segment by Application

Hospital

Clinic

Other

Anti-amyloid-β Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-amyloid-β Monoclonal Antibodies status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-amyloid-β Monoclonal Antibodies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-amyloid-β Monoclonal Antibodies significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-amyloid-β Monoclonal Antibodies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-amyloid-β Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-amyloid-β Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-amyloid-β Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-amyloid-β Monoclonal Antibodies market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-amyloid-β Monoclonal Antibodies industry.

Chapter 3: Detailed analysis of Anti-amyloid-β Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-amyloid-β Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-amyloid-β Monoclonal Antibodies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-amyloid-β Monoclonal Antibodies Industry Trends Table 2. Anti-amyloid-β Monoclonal Antibodies Industry Drivers Table 3. Anti-amyloid-β Monoclonal Antibodies Industry Opportunities and Challenges Table 4. Anti-amyloid-β Monoclonal Antibodies Industry Restraints Table 5. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-amyloid-β Monoclonal Antibodies Revenue Share by Company (2021-2026) Table 7. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Company (2021-2026) Table 9. Global Anti-amyloid-β Monoclonal Antibodies Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Anti-amyloid-β Monoclonal Antibodies Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-amyloid-β Monoclonal Antibodies Key Company Manufacturing Base & Headquarters Table 12. Global Anti-amyloid-β Monoclonal Antibodies Company, Product Type & Application Table 13. Global Anti-amyloid-β Monoclonal Antibodies Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-amyloid-β Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lecanemab Table 18. Significant Companies of Donanemab Table 19. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Type (2021-2026) Table 23. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Type (2027-2032) Table 24. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type (2021-2026) Table 28. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Application (2021-2026) Table 36. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Application (2027-2032) Table 37. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application (2021-2026) Table 41. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application (2027-2032) Table 42. Global Anti-amyloid-β Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Anti-amyloid-β Monoclonal Antibodies Sales by Region (2021-2026) & (K Units) Table 44. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Region (2021-2026) Table 45. Global Anti-amyloid-β Monoclonal Antibodies Sales by Region (2027-2032) & (K Units) Table 46. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Region (2027-2032) Table 47. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Region (2021-2026) Table 50. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Region (2027-2032) Table 52. Global Anti-amyloid-β Monoclonal Antibodies Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Anti-amyloid-β Monoclonal Antibodies Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Anti-amyloid-β Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 57. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 58. Global Anti-amyloid-β Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 59. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Country (2027-2032) Table 60. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Market Share by Country (2021-2026) Table 62. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Market Share by Country (2027-2032) Table 64. Eisai Company Information Table 65. Eisai Business Overview Table 66. Eisai Anti-amyloid-β Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Eisai Anti-amyloid-β Monoclonal Antibodies Product Portfolio Table 68. Eisai Recent Development Table 69. Eli Lilly Company Information Table 70. Eli Lilly Business Overview Table 71. Eli Lilly Anti-amyloid-β Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Eli Lilly Anti-amyloid-β Monoclonal Antibodies Product Portfolio Table 73. Eli Lilly Recent Development Table 74. Biogen Company Information Table 75. Biogen Business Overview Table 76. Biogen Anti-amyloid-β Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Biogen Anti-amyloid-β Monoclonal Antibodies Product Portfolio Table 78. Biogen Recent Development Table 79. Key Raw Materials Table 80. Raw Materials Key Suppliers Table 81. Anti-amyloid-β Monoclonal Antibodies Distributors List Table 82. Anti-amyloid-β Monoclonal Antibodies Customers List Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Anti-amyloid-β Monoclonal Antibodies Product Image Figure 2. Global Anti-amyloid-β Monoclonal Antibodies Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-amyloid-β Monoclonal Antibodies Sales (2021-2032) & (K Units) Figure 5. Global Anti-amyloid-β Monoclonal Antibodies Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Anti-amyloid-β Monoclonal Antibodies Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lecanemab Image Figure 10. Donanemab Image Figure 11. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Type (2021-2032) Figure 14. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Application (2021-2032) Figure 23. Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application (2021-2032) Figure 26. Global Anti-amyloid-β Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 31. North America Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 37. South America Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Anti-amyloid-β Monoclonal Antibodies Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Anti-amyloid-β Monoclonal Antibodies Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Lecanemab
  • Donanemab
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Eisai
  • Eli Lilly
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032)
  4. 1.2.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-amyloid-β Monoclonal Antibodies Market Dynamics
  1. 2.1 Anti-amyloid-β Monoclonal Antibodies Industry Trends
  2. 2.2 Anti-amyloid-β Monoclonal Antibodies Industry Drivers
  3. 2.3 Anti-amyloid-β Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 Anti-amyloid-β Monoclonal Antibodies Industry Restraints
3 Anti-amyloid-β Monoclonal Antibodies Market by Company
  1. 3.1 Global Anti-amyloid-β Monoclonal Antibodies Company Revenue Ranking in 2025
  2. 3.2 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Company (2021-2026)
  3. 3.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-amyloid-β Monoclonal Antibodies Average Price by Company (2021-2026)
  5. 3.5 Global Anti-amyloid-β Monoclonal Antibodies Company Ranking (2024-2026)
  6. 3.6 Global Anti-amyloid-β Monoclonal Antibodies Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-amyloid-β Monoclonal Antibodies Company Product Type and Application
  8. 3.8 Global Anti-amyloid-β Monoclonal Antibodies Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-amyloid-β Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-amyloid-β Monoclonal Antibodies Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-amyloid-β Monoclonal Antibodies Market by Type
  1. 4.1 Anti-amyloid-β Monoclonal Antibodies Type Introduction
  2. 4.1.1 Lecanemab
  3. 4.1.2 Donanemab
  4. 4.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Type
  5. 4.2.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Type
  9. 4.3.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type (2021-2032)
5 Anti-amyloid-β Monoclonal Antibodies Market by Application
  1. 5.1 Anti-amyloid-β Monoclonal Antibodies Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Application
  6. 5.2.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Application
  10. 5.3.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Application (2021-2032)
  12. 5.3.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application (2021-2032)
6 Anti-amyloid-β Monoclonal Antibodies Regional Sales and Value Analysis
  1. 6.1 Global Anti-amyloid-β Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-amyloid-β Monoclonal Antibodies Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Region (2027-2032)
  5. 6.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-amyloid-β Monoclonal Antibodies Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032)
  12. 6.6.2 North America Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032)
  21. 6.9.2 South America Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
7 Anti-amyloid-β Monoclonal Antibodies Country-level Sales and Value Analysis
  1. 7.1 Global Anti-amyloid-β Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Country (2027-2032)
  6. 7.4 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-amyloid-β Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-amyloid-β Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Anti-amyloid-β Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Anti-amyloid-β Monoclonal Antibodies Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Anti-amyloid-β Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Anti-amyloid-β Monoclonal Antibodies Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Biogen
  14. 8.3.1 Biogen Company Information
  15. 8.3.2 Biogen Business Overview
  16. 8.3.3 Biogen Anti-amyloid-β Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Biogen Anti-amyloid-β Monoclonal Antibodies Product Portfolio
  18. 8.3.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-amyloid-β Monoclonal Antibodies Value Chain Analysis
  2. 9.1.1 Anti-amyloid-β Monoclonal Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-amyloid-β Monoclonal Antibodies Sales Mode & Process
  6. 9.2 Anti-amyloid-β Monoclonal Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-amyloid-β Monoclonal Antibodies Distributors
  9. 9.2.3 Anti-amyloid-β Monoclonal Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst